The board of directors consists of experienced members from the biotechnology industry.
Christine Widstrand is the EVP of LU Innovation AB ( Lund University's holding company ) that supports and finances start -up companies and licensing deals coming from university research. Christine is responsible for the Life Science portfolio . She has > 15 years of experience in research and development, including the start-up of academic companies. Valuable in this context is her international experience around the financing, licensing , sales and marketing obtained from roles as co-founder and / or director of several life science companies. Christine is one of the founders of MIP Technologies AB, now part of Biotage, where she had various management positions (CEO , CBO) 2000-2009. Christine has a PhD in Analytical Chemistry at Lund University .
Johan Evenäs received a PhD in biophysical chemistry at LTH and carried out post-doctoral studies within NMR structural biology at Univ. of Toronto (1999-2001). He was then recruited to AstraZeneca where he was a highly rated projects and chemistry leader in early drug projects covering both internal resources and external (outsourcing). Johan was also Secretary of the global patent Committee for Airway & Inflammation. He has complemented his scientific knowledge and professional experience with courses in leadership, entrepreneurship, finance, marketing, and trade & and intellectual property law. Johan has 19 scientific articles and is co-inventor on three patents. He is CEO of RGD since its launch in 2011.
Prof. Søren Nielsen, MD, PhD, Aalborg Universitet Prof. Nielsen is the world's leading scientists in the field of cellular/molecular biology, physiological and pathological studies of aquaporins, sodium channels and transporters with > 380 articles. He brings to ApoGlyX also invaluable business knowledge through their experience with Action Pharma where he was co-founder and Executive (2001-2010 CEO, 2010-2012 COO) and € 30 million went to conduct clinical trials (Phase 2a & 2b) with AP214 – a candidate for acute renal failure – in Europe and the United States. Ap214 was acquired in May 2012 by Abbott, Chicago (~ $ 110 million). Prof. Nielsen is in addition to its academic role, also the CEO of SynAct Pharma which acquired Action Pharma's other development programs by 2012. For his research, he received several awards (Novo Nordisk Prize, the Novo Nordisk Foundation 2009).
Prof. Per Kjellbom, PhD, Biochemistry and Structural biology, Lund University Prof. Kjellbom holds a PhD in plant biochemistry, LU since 1987. He performed postdoctoral studies at the Salk Institute for Biological Studies, La Jolla, California, United States (1987-1989). He is head of Division since 2010 for Biochemistry & structural biology at Lund University, and member of the Swedish National Committee for Molecular Biosciences at the Royal Academy of Sciences. Professor Kjellbom is a world leader in aquaporin-research and has over 60 scientific articles. He has previously been the CEO of Hydrogene Lund AB, a small biotechnology company focused on the commercial application of knowledge relating to aquaporin in biotechnology and medicine.
Preben Bruun-Nyzell is an independent investor with more than 20 years experience in finance and finance systems. He was previously Chief Finanacial Officer of Qatalum in Qatar, an aluminium producer with annual sales of USD 1.5 bn, and has held senior positions with EMAL in Abu Dhabi, Arqaam Capital in Dubai, Accenture and PwC in London and Hoffmann-La Roche AG in Basel, Switzerland. Preben holds a degree in Business Administration from Lancaster University in the UK and Universita Bocconi, Milan, Italy. He is currently based in Sweden where he runs an investment business.